戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ontinuous complete remission for >/=5 years) was achieved in 3%.
2 aseline inducible VT, and VT noninducibility was achieved in 69%.
3 freedom from recurrent AF/atrial tachycardia was achieved in 87%.
4               Elimination of the targeted VT was achieved in 90%.
5            Under rate control, rate criteria were achieved in 96%.
6 tion was fast and the adsorption equilibrium was achieved in 30min.
7 ied success (IOP </=21 mmHg with medication) was achieved in 35.0% and 7.5%, respectively (P = 0.003)
8  success (IOP </=21 mmHg without medication) was achieved in 35.0% eyes of the ALPI group compared wi
9 uccess (IOP </=21 mm Hg without medications) was achieved in 60.0% eyes of the SLT group, compared wi
10              Virological eradication/control was achieved in 34.1% of HCV and 88.6% of HBV patients a
11          Possible sustained unresponsiveness was achieved in 82.1% receiving PPOIT and 3.6% receiving
12              A final BCVA of 20/40 or better was achieved in 6/10 (60%) of eyes.
13 e 16-week regimen with and without ribavirin was achieved in 26 (100% [95% CI 87-100]) of 26 particip
14                     Major molecular response was achieved in 43% (100 mg once daily) and 40% (all oth
15                                        SVR12 was achieved in 70% (101/145) versus 68% (100/146) of pr
16                            Complete response was achieved in 65% (11 of 17) of patients at minimum fo
17                At week 52, treatment success was achieved in 3 (12%) placebo-treated participants, 11
18  undetectable at end of treatment, and SVR12 was achieved in 102/120 (85%) patients, with 7 relapses,
19        Postoperative CDVA of 20/20 and 20/30 was achieved in 75% (15 eyes) and 25% (5 eyes), respecti
20                    R0, R1, and R2 resections were achieved in 78, 15, and 7 cases, respectively.
21    In the IMCT group, 360-degree cannulation was achieved in 80% (16/20) of eyes.
22 he per-protocol (PP) analysis, adjusted-ACPR was achieved in 100% (165/165) and 93.6% (161/172) of pa
23                  Clinical success at 28 days was achieved in 49% (18/37) of patients who received ant
24             Complete hematological remission was achieved in 153/180 (85%) patients and 27 (15%) died
25                 Confirmed objective response was achieved in 52 (19.6%, 95% CI 15.0-24.9) of 265 pati
26             Overall sustained viral response was achieved in 122/199 patients, 46/109 infected by dif
27                Viral consensus sequences can be achieved in 1-2 d by starting with clinical samples a
28             Driving vision (20/40 or better) was achieved in 43.2% of treated eyes.
29 pid international normalized ratio reduction was achieved in 62.2% of patients receiving 4F-PCC versu
30 canalization with the balloon guide catheter was achieved in 89.2% of thrombectomies (91 of 102) vers
31 dex limb at 30 days (+ 7 days) postprocedure was achieved in 99.2% (258/260) of patients (P < 0.001).
32 giographic, procedural, and clinical success was achieved in 99.2%, 99.1%, 98.3%, and 96.6% of cases,
33         Absent, incomplete, and complete STR were achieved in 514 (20.7%), 712 (28.7%), and 1258 (50.
34                                          pCR was achieved in 19% (21 of 111) of cases; 86% of them we
35               Successful epicardial ablation was achieved in 5 (22%) patients.
36 med investigator-assessed objective response was achieved in 19 (24.4%, 95% CI 15.3-35.4) of 78 patie
37                              Freedom from AF was achieved in 21/26 (81%) at 6 months off antiarrhythm
38           Among GT3-infected patients, SVR12 was achieved in 96% (27 of 28; 95% CI, 82-99) of patient
39                  Gross total resection (GTR) was achieved in 16/27 (59.3%) patients, subtotal resecti
40                 Confirmed objective response was achieved in 23 (28.4%, 95% CI 18.9-39.5) of the 81 p
41 is suppurativa clinical response at 12 weeks was achieved in 30% (3 of 10) of the placebo arm and in
42             Ablation of the clinical VT only was achieved in 18.3% of ICM and in 22.2% of NIDCM patie
43                           Procedural success was achieved in 99.3% and 96.6% of BRS- and DES-treated
44                              Patient benefit was achieved in 12 (30.0%; 95% CI 16.6-46.5) patients gi
45                                  HIV testing was achieved in 131,307 (89%) of 146,906 adults with sta
46  durable reduction in MR to </=2+ at 30 days was achieved in 5 (33.3%) of the first 15 patients and 1
47                    Complete clinical success was achieved in 259 (37%) of 705 patients, with a wide v
48           Significant enhancement of potency was achieved in 5-(4-aminobutyl)-N(4)-butyl-6-methylpyri
49 ity during programmed electrical stimulation was achieved in 34.4% and 19.2% of patients, respectivel
50                     Bacterial identification was achieved in 43.4%.
51 xcellent outcome (modified Rankin Score 0-1) was achieved in 47.4% (236/498) of direct patients versu
52                         Effective hemostasis was achieved in 72.4% of patients receiving 4F-PCC versu
53 eek 48, HIV-1 RNA less than 50 copies per mL was achieved in 92.4% of patients (n=290 of 314) in the
54                 A likely molecular diagnosis was achieved in 110 (40%) unrelated probands.
55               At week 16, a PASI 75 response was achieved in 37 (41%) patients in the methotrexate gr
56 of approaches, a confirmed genetic diagnosis was achieved in 51% (43 of 85).
57                   Favorable overall response was achieved in 113 (46.5%) patients by week 2.
58                           Diabetes remission was achieved in 68 (46%) participants in the interventio
59                Confirmed objective responses were achieved in 18 (47% [95% CI 31-64]) patients in the
60                           Complete resection was achieved in 86.5% of patients (n = 697) in ADC, 69.5
61  gradient reduction to </=20 and </=10 mm Hg was achieved in 89.5% (95% confidence interval, 83.7-95.
62 ection of congenital intrahepatic bile ducts was achieved in 90.5% of the 148 patients who underwent
63        Relief from pressure-related symptoms was achieved in 98.5%, and durable remission of anemia a
64 -121 months) were recruited, and a diagnosis was achieved in 23 (52%) by singleton WES.
65                   Complete clinical response was achieved in 492 (52%) of 940 patients at assessment
66                        Overall acute success was achieved in 16 (53%) patients.
67 ntact to device activation within 90 minutes was achieved in 913 (54.1%) patients.
68                          Rapid INR reduction was achieved in 48 (55%) patients in the 4F-PCC group co
69                             Clinical success was achieved in 40/55 (73%) patients treated with minocy
70                        Freedom from AF or AT was achieved in 44 (56%), 39 (48%), and 61 (74%) patient
71 1% or greater, confirmed objective responses were achieved in 12 (57%) of 21 patients in the ipilimum
72                           At week 16, PASI75 was achieved in 22 (58%) of 38 patients in the adalimuma
73  the 160 patients, and TICI 2b-3 reperfusion was achieved in 94 (59%) patients.
74                             Clinical success was achieved in 70.59% of eyes in the ipsilateral group
75  virologic response at posttreatment week 12 was achieved in 100% (6/6, 95% confidence interval 61-10
76                           Complete remission was achieved in 40% (6/15 of evaluable patients) and med
77                        A molecular diagnosis was achieved in 62.6% of patients with CMT attending the
78 reatment-free interval of 3 months or longer was achieved in 92.6% and 83.5% of the patients randomiz
79                  Complete VT noninducibility was achieved in 62 (61%) patients and partial success or
80                          Haematocrit control was achieved in 46 (62%) of 74 ruxolitinib-treated patie
81 ents and pharmacological control of symptoms was achieved in 141 (64%) patients.
82          Successful sustained ablation (SSA) was achieved in 53 (66%) patients, and LVEF improved in
83                          Stage II palliation was achieved in 92 (67%) patients (Sano: 7; Norwood: 51;
84 d in six (3%) patients and partial responses were achieved in 134 (67%) patients.
85 s, single-procedure arrhythmia-free survival was achieved in 58.7% of patients.
86 ucibility of any clinical and nonclinical VT was achieved in 66.7% of NIDCM and in 77.4% of ICM patie
87       Adequate glycemic control (HbA1c < 7%) was achieved in 66.7% of the patients.
88                     Ocular surface stability was achieved in 72.7% (120/165) of eyes at last follow-u
89                         The area of interest was achieved in 80.7% of the cases, with a 5.5% rate of
90                  At 1 year, absolute success was achieved in 86.7% (26/30) and 90.0% (27/30) in Group
91                                        SVR12 was achieved in 94.7% (18 of 19), 97.6% (40 of 41), and
92   Adequate anesthesia and akinesia (grade 5) were achieved in 56.7% of the patients in the bupivacain
93  and transection of the anatomic isthmus and was achieved in 25 (74%) patients.
94                                 An R0 margin was achieved in 36 (74%) patients.
95                         Retinal reattachment was achieved in 10 (76%) eyes after the first operation
96 f 23 patients, and device success at 30 days was achieved in 18 (78%) patients.
97     In the phase 2 part, an overall response was achieved in 29 (78% [95% CI 62-91]) of 37 patients.
98 ), an overall response by independent review was achieved in 85 (79.4%; 95% CI 70.5-86.6) of 107 pati
99                              Angiographic CR was achieved in 52.8% of the PCI arm and 66.9% of the CA
100                                          SVR was achieved in 56.8% (95% confidence interval [CI]: 45.
101                                Effectiveness was achieved in 67.8% and 69.4% of subjects in the CF an
102 itiating infliximab, control of inflammation was achieved in 81.8% at 6 months and in 88.9% at the 1-
103 Sixty-nine patients started treatment; SVR24 was achieved in 55 (80% [95% confidence interval, 68%-88
104 tinal attachment after silicone oil removal) was achieved in 20 (83.3%) eyes at the end of follow-up,
105  with FNAB, a successful cytologic diagnosis was achieved in 176 (84%).
106                                           CI was achieved in 37 (84%) and led to better VT-free survi
107 e pulmonary vein (PV) isolation with CB only was achieved in 99.86% and 100% of veins with CBG1 and C
108 t within 6 months without further treatment, was achieved in 29 (87.9%) eyes.
109                                Acute success was achieved in 66 (88%) patients in group 1, 68 (81%) i
110            Primary stricture resolution rate was achieved in 17 (89.5%) of 19 patients.
111      At week 48, HIV-1 RNA <50 copies per mL was achieved in 286 (89%) of 320 participants in the bic
112 erilization of the operative specimen, which was achieved in 13.9% versus 19.2% of patients, respecti
113                                      Control was achieved in 38.9% of intervention and 39.1% of contr
114                            Complete necrosis was achieved in 50.9% and 57.1% of cTACE and DEB-TACE pa
115               Noninducibility of targeted VT was achieved in 75.9% of patients.
116 0 g) and nonoptimal CF groups, effectiveness was achieved in 75.9% versus 58.1%, respectively (P=0.01
117 imary patency at 12 months (360 +/- 30 days) was achieved in 78.9% (180/228) of the population (P < 0
118 ollow-up was 2 years, and complete follow-up was achieved in 99.9% of patients.
119                        Effective haemostasis was achieved in 78 (90%) patients in the 4F-PCC group co
120                              Disease control was achieved in 21 (91%; 95% CI 72.0-98.9) of 23 patient
121  improvement of best-corrected visual acuity was achieved in 22 (91.7%) eyes.
122                         The primary endpoint was achieved in 151 (92%) participants with latent yaws
123                                        SVR12 was achieved in 154 (92%) patients (n=72 [90%, 95% CI 81
124            Results Primary technical success was achieved in 33 (92%) patients who underwent a single
125 irological response (SVR) at week 12 (SVR12) was achieved in 78% (92 of 118) of patients (95% confide
126  and uprifosbuvir with and without ribavirin was achieved in 39 (93% [95% CI 81-99]) of 42 participan
127                    Results Complete ablation was achieved in 40 (93%; 95% CI: 85, 100) of 43 target t
128 nd of therapy, sustained virologic responses were achieved in 89%, 93%, 91%, and 86% of the patients
129 ydro-1,2,4-benzothiadiazine-1,1-dioxides has been achieved in 39-94% yield through palladium-catalyze
130  compassionate use cohort, technical success was achieved in 22 (96%) of 23 patients, and device succ
131 e 12-week regimen with and without ribavirin was achieved in 28 (97% [95% CI 82-100]) of 29 of those
132            Among treatment completers, SVR12 was achieved in 441 (97.1%) of PPI recipients compared w
133                                        SVR12 was achieved in 57 (97%; 97.5% CI 86.7-99.2) of 59 patie
134 e 12-week regimen with and without ribavirin was achieved in 87 (99% [95% CI 94-100]) of 88 participa
135                              Disease control was achieved in 81%, although 38.5% had profound visual
136 centration with K. lactis beta-galactosidase was achieved in 1 and 5h at 40 and 4 degrees C, respecti
137 idation of cryptocaryol A and cryptocaryol B were achieved in 23 and 25 linear steps, respectively.
138 response 12 weeks after the end of treatment was achieved in 95% and 93% of the patients, respectivel
139  26, mucosal healing and endoscopic response were achieved in 48% and 65% of patients, respectively.
140    After ablation, complete LAVA elimination was achieved in 60%, and VT noninducibility in 83%.
141 ted animals, complete atrioventricular block was achieved in 6 animals of all 4 dose groups (86%).
142           Confirmed major molecular response was achieved in 64% at 12 months and 73% at 24 months.
143 ET imaging shows that prominent tumor uptake was achieved in 4T1 breast cancer with (64)Cu-LDH-BSA vi
144                                Globe salvage was achieved in 10 cases, as 1 patient required enucleat
145                         Initial reattachment was achieved in 139 cases (94.5%; 95% confidence interva
146                           Final reattachment was achieved in 147 cases (100%).
147                 Postoperative BSCVA >/=20/25 was achieved in 14 eyes (38.9%), whereas a BSCVA of 20/3
148                           Anatomical success was achieved in 14 eyes.
149          Successful reattachment at 2 months was achieved in 171 eyes (66.3%).
150 e resolution of fluid in and under the fovea was achieved in 17 eyes (94%) without additional treatme
151 ional operation and final anatomical success was achieved in 256 eyes (99.2%).
152 ision (defined as losing 5 letters or fewer) was achieved in 28 eyes (90.3%).
153  27 eyes whose disease resolved, this result was achieved in 4 eyes with medical treatment, in 7 pseu
154                                   Big bubble was achieved in 5 eyes, while manual dissection was done
155 ry, 20/40 visual acuity or better (>/=20/40) was achieved in 68% following phacoemulsification, 72% f
156 H2O2 concentration of approximately 230 mg/L was achieved in 6 h of batch cathode operation.
157 s, a complete resolution of subretinal fluid was achieved in 26 half-fluence-treated eyes (83.9%) and
158                            Technical success was achieved in 85% in fTRA and 86% in TFA (P=0.51).
159               Overall, a molecular diagnosis was achieved in 102 infants (36.7%) by clinical exome se
160 sis of the putative structure of diplopyrone was achieved in 17 linear steps starting from cis-1,4-bu
161 onvergent total synthesis of Leustroducsin B was achieved in 17 longest linear and 39 total steps by
162                                  Reperfusion was achieved in 27 LTB patients (67.5%) and 24 UTB patie
163    A baseline separation of the 20 phenolics was achieved in 25 min with standard calibration curves
164 (acute retrieval cohort), complete retrieval was achieved in 100% (n=5/5); for those implanted for >/
165                  Complete procedural success was achieved in 50% (n=8) of patients, who were initiall
166  weeks (chronic retrieval cohort), retrieval was achieved in 91% (n=10/11) of patients.
167                            Technical success was achieved in 100 of 103 US-guided procedures (97.1%)
168      Prespecified acute procedural end point was achieved in 12 of 24 (50%) patients: AF termination
169                 Clinical response at week 12 was achieved in 14 of 20 (70.0%) control patients, 19 of
170 ellen 20/538, P = .04), retinal reattachment was achieved in 14 of 20 eyes (70%), and ERM formation w
171                    Successful recanalization was achieved in 14 of 22 occlusion patients (64%) and in
172                  Clinical procedural success was achieved in 160 of 164 patients (97.6%), whereas 4 (
173 nual operation, and device technical success was achieved in 162 of 164 patients (98.8%).
174                                     Response was achieved in 16 of 85 (19%) patients allocated to the
175 f 204 patients (96.6%), and clinical success was achieved in 174 of 204 (85.3%).
176                                 HRS reversal was achieved in 23 of 97 (23.7%) patients receiving terl
177                             A VA of >/=20/40 was achieved in 24 of 63 (38%) eyes.
178 ellen 20/538, P = .64), retinal reattachment was achieved in 25 of 35 eyes (71%), and ERM formation w
179       Chronic isolation (mean, 48+/-16 days) was achieved in 27 of 36 PVs (75%).
180 of bedaquiline treatment, culture conversion was achieved in 28 of 29 (97%) cases with culture-positi
181                                Globe salvage was achieved in 2 of 2 group C eyes (100%), 3 of 3 group
182 tinib plus vinorelbine, and clinical benefit was achieved in 2 of 4 trastuzumab-treated and 0 of 6 tr
183  14 patients, and reattachment of the retina was achieved in 2 of 5 patients after the first vitrecto
184                                          pCR was achieved in 30 of the 85 tumors (35%).
185                        In particular, an SVR was achieved in 31 of 44 (70.5%), 31 of 43 (72.1%), and
186 nual separation without any disruption of DM was achieved in 335 of 350 donor corneas (95.7%) by use
187 on the 12-lead electrocardiogram at 1 month, was achieved in 33 of 34 patients.
188                      Adequate recanalization was achieved in 34 of 38 cases (89%).
189                                 Acutely, PVI was achieved in 36 of 40 PVs (90%).
190                           NSAA >/= 0.1 IU/mL was achieved in 38 of 41 patients (92.7%) with acceptabl
191                            Closure of the MH was achieved in 39 of 47 eyes (83%) in the study group a
192                            Treatment success was achieved in 3 of 8 children in cohort 1 compared wit
193 l endoscopic clearance of all polyps >/=3 mm was achieved in 41 of 50 (82%) patients.
194             A pathological complete response was achieved in 47 of 161 patients (29%) who underwent r
195 and nonsurgical closure of full-thickness MH was achieved in 4 of 15 eyes (27%).
196  recanalization after endovascular treatment was achieved in 50 of 54 (92.6%) patients.
197                            Technical success was achieved in 51 of 51 lesions (100%) with DBT VAB ver
198                          Bidirectional block was achieved in 56 of 57 patients in group A (98.2%) and
199 ythmia freedom at 13 months median follow-up was achieved in 59 of 85 (69%) patients in group I, whic
200                                        SVR12 was achieved in 62 of the 102 patients (60.8%).
201              Complete spectacle independence was achieved in 69 of 84 (82.1%) AT LISA 809M recipients
202                            Successful access was achieved in 6 of 10 patients with prior coronary art
203  Permanent resolution of vitreous hemorrhage was achieved in 6 of 14 patients, and reattachment of th
204 plete clinical resolution of the CIN lesions was achieved in 87 of the 89 eyes treated (97.75%).
205           A pCR in the primary breast cancer was achieved in 9 of 51 patients.
206 was well tolerated, and 100% histologic cure was achieved in 9 of 9 assessable animals without detect
207                          Successful outcomes were achieved in 9 of 14 patients (64%) treated with med
208 ostic rate was 82.9%; unaffected live births were achieved in 9 of 20 FET cycles (45%), with only one
209 dergo transplantation in CR1 and relapse can be achieved in 19% of patients, which is improved by a t
210 a complete ablation of all inducible VTs may be achieved in 60% of the cases.
211 oncordance of LV lead with latest site could be achieved in 85% of the EG group and occurred fortuito
212                            Technical success was achieved in 100% of cases.
213                      Control of inflammation was achieved in 100% of patients.
214                              Donor chimerism was achieved in 20% of recipients conditioned with MR1/R
215                        The primary end point was achieved in 21% of the patients in the ruxolitinib g
216             A complete hematologic remission was achieved in 24% of patients in the ruxolitinib group
217                        Disease stabilization was achieved in 41% of patients at EoT (n = 14 of 34 tre
218                      A 50% reduction in TLG* was achieved in 46% of metastases and in 11 of 30 (37%)
219              Minimal response (MR) or better was achieved in 47% of patients (90% confidence interval
220            Successful temporary LVAD weaning was achieved in 50% of MPC and 20% of control patients a
221 nse at 6 months (platelets >/=100 x 10(9)/L) was achieved in 50% of patients and response at 6 months
222                    MFC-MRD negativity, which was achieved in 51% of patients after C1 (n = 286) and 6
223                Follow-up of at least 3 years was achieved in 51% of patients.
224                          A genetic diagnosis was achieved in 57% of all familial ataxias.
225 with a complete (R0) resection is 44%, which was achieved in 59% of patients.
226                           Hematocrit control was achieved in 60% of patients receiving ruxolitinib an
227                     Good HIV disease control was achieved in 60% of the patients (mean, 255 patients)
228 pia (spherical equivalent -0.5 to 0 diopter) was achieved in 61% of first DSBCS eyes, 61% of second D
229                          The primary outcome was achieved in 64% of patients (95% confidence interval
230         First door-to-device </= 120 minutes was achieved in 65% of patients (n = 9380); only 37% of
231 arabine and daunorubicin, complete remission was achieved in 65% of patients.
232   Revascularization in the embolectomy group was achieved in 67% of the patients.
233                     The ORR was 95% and a CR was achieved in 68% of patients.
234 and 138 the HMII), survival free of any HRAE was achieved in 69% of the HM3 group and in 55% of the H
235                    Procedural AF termination was achieved in 70% of patients, but decreased with long
236                                           TO was achieved in 71% of EVAR and 53% of OSR.
237 a mean follow-up of 19 months, globe salvage was achieved in 72% of primary-treated cases and in 62%
238                            Treatment success was achieved in 74% of patients on 1 immunosuppressant,
239                        First-attempt success was achieved in 74% of the Glidescope video laryngoscopy
240  of 42 months, complete hematologic response was achieved in 76% of patients with PV and 77% of those
241                 A partial response or better was achieved in 79% of patients in the treatment group a
242                        Overall acute success was achieved in 81% of the patients.
243 abbit hearts, the successful induction of VF was achieved in 83% of attempts in controls versus 41% i
244  rate was 67%, and at least minimal response was achieved in 83% of the patients.
245                At week 48, virologic success was achieved in 85% of COBI recipients and 87% of RTV re
246 lation (systolic blood pressure >/=60 mm Hg) was achieved in 85% of the dantrolene group in compariso
247                            Complete response was achieved in 89% of older patients, 3% had progressiv
248  12 weeks after treatment completion (SVR12) was achieved in 90% of patients (95% confidence interval
249 CC TVT Registry, device implantation success was achieved in 92% of cases, the overall in-hospital mo
250 increase in Hb of >/=1.0 g/dl from baseline) was achieved in 96% of efficacy-evaluable patients.
251 d in 53% of patients, and complete responses were achieved in 21% of patients.
252 nds, in which rank-1 sum formula assignments were achieved in 84% of the cases, compared to only 63%
253        A reduction of concomitant medication was achieved in 1 patient.
254                 A definitive diagnosis could be achieved in 37 patients with 39 MDCT masses (22 throm
255                            Complete ablation was achieved in 10 patients (83.3%), and the alpha-fetop
256                                   PS-R0-neck was achieved in 1196 patients (85.5%), 131 patients (9.3
257             Native biventricular circulation was achieved in 12 patients after staged LV recruitment;
258                       Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8
259                       Resolution of diarrhea was achieved in 14 patients (70%; 95% CI, 47%-85%) after
260                        The primary end point was achieved in 164 patients in the study group and 85 p
261 cess (noninducibility of any monomorphic VT) was achieved in 17 patients (38%), partial success (elim
262                       A successful resection was achieved in 194 patients (82%) in the laparoscopic s
263                           Complete remission was achieved in 23 patients (18%), 36 (27%) had a partia
264                               Stable disease was achieved in 23 patients.
265      Complete remission or partial remission was achieved in 247 patients (76%).
266                            Complete response was achieved in 24 patients (complete response rate, 63%
267 events (26%) for which return of circulation was achieved in 25 patients (93%).
268  and reduction of MR from 3+ or 4+ to </=2+) was achieved in 26 patients (86.7%).
269                           Complete remission was achieved in 27 patients (90%), including 2 patients
270               Successful device implantation was achieved in 28 patients (93.3%).
271                       A successful resection was achieved in 292 patients (50.8%).
272                  Sustained disease remission was achieved in 2 patients undergoing HSCT (8.7%) vs 1 c
273                           Four-hour survival was achieved in 307 patients (23.6%) with mechanical CPR
274                                          pCR was achieved in 30 patients (22%); 37% SCC and 17% adeno
275   Spectacle independency for distance vision was achieved in 31 patients (84%) in the toric group com
276                             Clinical benefit was achieved in 31 patients treated for one infection an
277         Complete resection (stages I and II) was achieved in 32 patients, and 28 patients had stage I
278                     Complete tumor resection was achieved in 34 patients (40%), including seven of th
279 artial, or minor response or stable disease) was achieved in 47 patients (87.0%).
280                                 R0 resection was achieved in 53 patients (94.6%).
281 he IP maneuver, complete CTI block (phase 2) was achieved in 59 patients, in 13 of whom an intermedia
282 response 12 weeks after the end of treatment was achieved in 6 patients (60%).
283                            Termination of VT was achieved in 6 patients at a mean ventricular activat
284                           Globe preservation was achieved in 80 patients (97.6%); 2 patients underwen
285  with afatinib monotherapy, clinical benefit was achieved in 9 patients (35%), 0 of 7 trastuzumab-tre
286                           A successful NJEEN was achieved in 63% patients.
287  309 ablation procedures in 277 patients and was achieved in 291 procedures (94%).
288 atural tubulin polymerization inhibitor, has been achieved in 12 steps starting from commercially ava
289 -methylwelwitindolinone D isonitrile (1) has been achieved in 17 steps from a readily available carvo
290 selective synthesis of (-)-himalensine A has been achieved in 22 steps.
291    The total synthesis of (+)-cryptocaryol A was achieved in 20 steps from (R)-glycidol.
292 e asymmetric synthesis of (-)-(S,S)-homaline was achieved in 8 steps and 18% overall yield, and the a
293  asymmetric synthesis of (-)-(R,R)-hopromine was achieved in 9 steps and 23% overall yield, from comm
294 lete success with IOP </= 21 mmHg at 8 years was achieved in 48 subjects (55.8%) in the 5-FU and 33 s
295                    Complete anatomic success was achieved in 61 subjects (53.5%), of whom 55 needed o
296                 Weight loss or stabilization was achieved in 96% subjects receiving TORe and 78% of c
297  control with resolution of subretinal fluid was achieved in 7 tumors (78%), with mean tumor thicknes
298  0% versus 4% (P = .925), and stable disease was achieved in 35% versus 17% of patients (P = .021).
299 rst significant step forward in clinical use was achieved in 2008 with the first human experience wit
300                         Intact TME specimens were achieved in 85%, with minor defects in 11% and majo

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top